ECM2026, 14-17 June 2026, Copenhagen, DenmarkCurrent trends on liver fibrosis assessment: Moving beyond the biopsy
Lise Lotte Gluud, Professor, Copenhagen University Hospital
Abstract: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a global health priority, yet the diagnostic rate remains low with less than 10% of diagnosed patients. Disease stage is critical for prognosis: MASLD with significant or advanced fibrosis is associated with liver-related complications but also increased risks of cardiovascular disease and extrahepatic cancers, whereas earlier stages primarily act as a risk state. Given the introduction of novel treatments, there is an urgent need for scalable and accurate diagnostic tools to identify patients eligible for therapy while reducing the burden on specialist care.
This session will be structured in 2 parts: in the first part we will discuss liver fibrosis assessment and evaluate Non-Invasive Testing (NIT) within current guidelines and clinical workups. The current NIT’s such as VCTE, ELF and ADAPT will be discussed and we will examine the latest development of the PRO-C3 assay as part of the ADAPT algorithm (incorporating PRO-C3, age, diabetes status, and platelet count) and its performance across validation cohorts. Central to this discussion is the implementation of sequential testing pathways, to refine diagnostic accuracy and optimize referral patterns from primary to secondary care.
In the second part, we will discuss the use of NIT’s to address the emerging unmet need for longitudinal treatment monitoring. We will explore how NITs can be implemented to monitor fibrosis dynamics, evaluate anti-fibrotic efficacy, and differentiate responders from non-responders. Consideration will also be given to the integration of NITs into treatment pathways, including their potential to support treatment decisions and care pathways.
Surrogate endpoints: Addressing challenges in complex chronic diseases
Veronica Miller, Adjunct Professor UC Berkeley
Abstract: TBD
